(29) suggest that ADT leads to the activation of CREB (cAMP response element-binding protein), which affects the neuroendocrine differentiation of prostate cancer through the CREB-EZH2-TSP1 pathway (EZH2: enhancer of zeste homolog 2, TSP1: thrombospondin-1, THBS1). This evidence concerns the gene EZH2 and prostate carcinoma.